Financial Daily from THE HINDU group of publications
Tuesday, Jul 06, 2004
Financial Daily from THE HINDU group of publications Tuesday, Jul 06, 2004 |
||
|
|
||
|
Corporate
-
People Rajinder Kumar is Ranbaxy's R&D head Our Bureau
New Delhi , July 5 FOLLOWING the exit of Dr Rashmi Bharbhaiya, President, Research and Development (R&D), from Ranbaxy Laboratories Ltd, the company has appointed Dr Rajinder Kumar as the new head. Dr Kumar, who was previously with GlaxoSmithKline (GSK), will report directly to Dr Brian W. Tempest, CEO and Managing Director of Ranbaxy. His appointment comes into effect from July 5. The new research head is a British national, who has been Global Head of Psychiatry - Clinical Research & Development at GSK, UK. He is a graduate from University of London, University of Birmingham and University of Dundee, UK, from where he holds a degree in Medicine and Surgery (MBChB) and a postgraduate qualification in Psychological Medicine from the Royal College of Surgeons and Physicians, Ireland. Dr Kumar has led a team of physicians and scientists who achieved a number of regulatory submissions and approvals in the US, the EU and Japan. This ultimately led to Paxil/Seroxat-paroxetine becoming the No. 1 product of the company and the first $2 billion product for the GSK.
More Stories on : People | Research & Development | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|